{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:43:48Z","timestamp":1787010228837,"version":"build-2736575974"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,3]]},"abstract":"<jats:p>Eltrombopag (ELT) is a thrombopoietin receptor activator that has shown efficacy in chronic immune thrombocytopenia. We report the outcome of ELT therapy in 4 children who were treated for rare hematologic disorders, including Pearson syndrome, DiGeorge syndrome, posttransplant allogeneic poor graft function (PGF), and Wiskott-Aldrich syndrome. The ELT tolerance in the analyzed group was good, with the exception of the child with Pearson syndrome, who experienced an exacerbation of cataracts and had to discontinue treatment. Thromboembolic events were observed in one child, who continued ELT therapy despite achieving normalized platelet counts. Independence from PLT transfusions was observed at the 4-week timepoint of therapy in patients with DiGeorge syndrome and PGF who responded to ELT. Discontinuation of therapy was successful in one child, who sustained the normal CBC values afterward. In 2 patients, an increase in neutrophil counts was observed during ELT therapy without additional intervention, and a positive correlation between neutrophil and platelet values during ELT therapy was observed in the child with PGF. ELT is effective in rare pediatric disorders, but response patterns are determined by the underlying disease. ELT shows promising results in patients, but constitutional hematopoiesis defects reduce the chances of a response.<\/jats:p>","DOI":"10.1097\/mph.0000000000001528","type":"journal-article","created":{"date-parts":[[2019,6,14]],"date-time":"2019-06-14T23:32:59Z","timestamp":1560555179000},"page":"113-117","source":"Crossref","is-referenced-by-count":9,"title":["Eltrombopag Therapy in Children With Rare Disorders Associated With Thrombocytopenia"],"prefix":"10.1097","volume":"42","author":[{"given":"Jowita","family":"Fr\u0105czkiewicz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorota","family":"S\u0119ga-Pondel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernarda","family":"Kazanowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Ussowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230918","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1634\/stemcells.2008-0366","article-title":"Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist","volume":"27","author":"Erickson-Miller","year":"2009","journal-title":"Stem Cells"},{"key":"R2-20230918","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/S0140-6736(15)61107-2","article-title":"Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial","volume":"386","author":"Grainger","year":"2015","journal-title":"Lancet"},{"key":"R3-20230918","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2174\/157488610790936196","article-title":"Safety of the thrombopoiesis-stimulating agents for the treatment of immune thrombocytopenia","volume":"5","author":"Cuker","year":"2010","journal-title":"Curr Drug Saf"},{"key":"R4-20230918","first-page":"113","article-title":"Pearson syndrome: a retrospective cohort study from the Marrow Failure Study Group of A.I.E.O.P. (Associazione Italiana Emato-Oncologia Pediatrica)","volume":"4","author":"Farruggia","year":"2015","journal-title":"JIMD Rep"},{"key":"R5-20230918","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1080\/17474086.2018.1426454","article-title":"Pearson syndrome","volume":"11","author":"Farruggia","year":"2018","journal-title":"Expert Rev Hematol"},{"key":"R6-20230918","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/MPH.0000000000001168","article-title":"Trilineage hematopoiesis induced by low-dose eltrombopag in a patient with fanconi anemia can be used as a bridge to hematopoietic stem cell transplant","volume":"41","author":"Gupta","year":"2019","journal-title":"J Pediatr Hematol Oncol"},{"key":"R7-20230918","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1160\/TH12-02-0121","article-title":"Eltrombopag fails to improve severe thrombocytopenia in late-stage dyskeratosis congenita and diamond-blackfan-anaemia","volume":"108","author":"Trautmann","year":"2012","journal-title":"Thromb Haemost"},{"key":"R8-20230918","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1160\/TH12-07-0522","article-title":"Function of eltrombopag-induced platelets compared to platelets from control patients with immune thrombocytopenia","volume":"109","author":"Haselboeck","year":"2013","journal-title":"Thromb Haemost"},{"key":"R9-20230918","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/j.bbmt.2013.10.002","article-title":"A phase 1 trial of eltrombopag in patients undergoing stem cell transplantation after total body irradiation","volume":"19","author":"Liesveld","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"R10-20230918","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJMoa1613878","article-title":"Eltrombopag added to standard immunosuppression for aplastic anemia","volume":"376","author":"Townsley","year":"2017","journal-title":"N Engl J Med"},{"key":"R11-20230918","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.stem.2007.10.020","article-title":"Thrombopoietin\/MPL signaling regulates hematopoietic stem cell quiescence and interaction with the osteoblastic niche","volume":"1","author":"Yoshihara","year":"2007","journal-title":"Cell Stem Cell"},{"key":"R12-20230918","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1200931","article-title":"Eltrombopag and improved hematopoiesis in refractory aplastic anemia","volume":"367","author":"Olnes","year":"2012","journal-title":"N Engl J Med"},{"key":"R13-20230918","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1182\/blood-2013-10-534743","article-title":"Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug","volume":"123","author":"Desmond","year":"2014","journal-title":"Blood"},{"key":"R14-20230918","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/5584_2014_38","article-title":"First-line immunosuppressive treatment in children with aplastic anemia: rabbit antithymocyte globulin","volume":"836","author":"Pawelec","year":"2015","journal-title":"Adv Exp Med Biol"},{"key":"R15-20230918","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.bbmt.2016.01.018","article-title":"Eltrombopag for treatment of thrombocytopenia after allogeneic hematopoietic cell transplantation","volume":"22","author":"Tanaka","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"R16-20230918","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1159\/000487229","article-title":"Use of eltrombopag in improving poor graft function after allogeneic hematopoietic stem cell transplantation","volume":"11","author":"Master","year":"2018","journal-title":"Case Rep Oncol"},{"key":"R17-20230918","doi-asserted-by":"crossref","first-page":"e13017","DOI":"10.1111\/petr.13017","article-title":"Eltrombopag for secondary failure of platelet recovery post-allogeneic hematopoietic stem cell transplant in children","volume":"21","author":"Ali","year":"2017","journal-title":"Pediatr Transplant"},{"key":"R18-20230918","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/MPH.0000000000001263","article-title":"Eltrombopag for delayed platelet recovery and secondary thrombocytopenia following allogeneic stem cell transplantation in children","volume":"41","author":"Li","year":"2019","journal-title":"J Pediatr Hematol Oncol"},{"key":"R19-20230918","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s13045-018-0649-6","article-title":"Successful treatment of secondary poor graft function post allogeneic hematopoietic stem cell transplantation with eltrombopag","volume":"11","author":"Tang","year":"2018","journal-title":"J Hematol Oncol"},{"key":"R20-20230918","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/bjh.15012","article-title":"CD34+selected stem cell boosts can improve poor graft function after paediatric allogeneic stem cell transplantation","volume":"180","author":"Mainardi","year":"2018","journal-title":"Br J Haematol"},{"key":"R21-20230918","first-page":"935","article-title":"A boost of CD34+-selected peripheral blood cells without further conditioning in patients with poor graft function following allogeneic stem cell transplantation","volume":"91","author":"Larocca","year":"2006","journal-title":"Haematologica"},{"key":"R22-20230918","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1182\/blood-2016-10-740241","article-title":"Eltrombopag: a powerful chelator of cellular or extracellular iron(III) alone or combined with a second chelator","volume":"130","author":"Vlachodimitropoulou","year":"2017","journal-title":"Blood"},{"key":"R23-20230918","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/5584_2015_148","article-title":"Influence of iron overload on immunosuppressive therapy in children with severe aplastic anemia","volume":"866","author":"Pawelec","year":"2015","journal-title":"Adv Exp Med Biol"},{"key":"R24-20230918","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/blood-2014-09-602573","article-title":"Effects of eltrombopag on platelet count and platelet activation in Wiskott-Aldrich syndrome\/X-linked thrombocytopenia","volume":"126","author":"Gerrits","year":"2015","journal-title":"Blood"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000001528","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T00:26:30Z","timestamp":1694996790000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000001528"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000001528","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]}}}